# reload+after+2024-01-22 20:46:58.562259
address1§611 Gateway Blvd
address2§Suite 900
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 624 1100
fax§650 624 1101
website§https://www.rigel.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
fullTimeEmployees§155
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Raul R. Rodriguez', 'age': 62, 'title': 'President, CEO & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 1093000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Dean L. Schorno CPA', 'age': 60, 'title': 'Executive VP & CFO', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 696670, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Raymond J. Furey J.D.', 'age': 55, 'title': 'Executive VP, General Counsel & Corporate Secretary', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 593458, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David A. Santos', 'age': 60, 'title': 'Executive VP & Chief Commercial Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 681635, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph  Lasaga', 'age': 48, 'title': 'Executive Vice President of Corporate Development', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Julie  Patel', 'title': 'Senior VP of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Esteban S. Masuda', 'age': 61, 'title': 'Executive Vice President of Research', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 537207, 'exercisedValue': 0, 'unexercisedValue': 6125}, {'maxAge': 1, 'name': 'Mr. Tarek  Sallam', 'title': 'Vice President of Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§4
compensationRisk§6
shareHolderRightsRisk§3
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.849
priceToSalesTrailing12Months§1.8600472
currency§USD
dateShortInterest§1702598400
forwardEps§-0.09
pegRatio§-0.11
exchange§NMS
quoteType§EQUITY
shortName§Rigel Pharmaceuticals, Inc.
longName§Rigel Pharmaceuticals, Inc.
firstTradeDateEpochUtc§975508200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§89fb242c-0941-386e-af47-a40b08f264ba
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.0
targetLowPrice§1.0
targetMeanPrice§4.04
targetMedianPrice§2.0
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§1.779
grossMargins§0.688
ebitdaMargins§-0.15559
trailingPegRatio§None
